Meet with... the National Cancer Institute

Add this event to your calendar:
18/06/2014 12:00 18/06/2014 15:00 America/Los_Angeles Meet with... the National Cancer Institute [email protected] , 953 Indiana Street , San Francisco , CA 94107 JLABS Bay Area false DD/MM/YYYY
June
18
Event

Meet with... the National Cancer Institute

[email protected] , 953 Indiana Street , San Francisco , CA 94107

June 18, 2014 from 12:00 PM to 15:00 PM (PST)

$10 - $35


SF BAY AREA EVENT Did you know that the National Cancer Institute SBIR & STTR is currently funding 372 projects in the areas of IT, diagnostics, imaging, devices, therapeutics and tools for basic research? Or that it is the oldest and largest funded institute within the NIH? Join us on June 18th for a chance to hear from a government program that is trailblazing healthcare innovation.

Program Overview:
NCI SBIR&STTR: Advancing the Commercialization of New Cancer Innovations

The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive financing for early stage companies, providing over $110M in fiscal year 2014 to develop next generation technologies. These initiatives help fill the gap in the availability of early stage funding created when investors and strategic partners move towards clinical-stage investments. SBIR/STTR funds serve as a key bridge between initial angel funding and more significant angel capital, venture capital, or strategic partnerships.

Presenting at this event will be Ming Zhao, PhD | Program Director, SBIR Development Center, National Cancer Institute and Todd Haim, PhD | Program Director, SBIR Development Center, National Cancer Institute. Dr. Zhao will provide valuable insights into SBIR/STTR eligibility requirements, the NIH SBIR/STTR process and the new cancer-focused grant funding opportunities. Dr. Haim will offer tips on preparing a successful competitive research proposals as well as new NCI SBIR/STTR initiatives.

Following the presentations selected companies will have the opportunity to meet one-on-one with directors. To be consider for one-on-one meetings please contact Brittany Connors at [email protected] by June 10th.

Agenda:
10:00am | Registration and Networking
10:30am | Presentation and Q&A
12:00pm | Networking Lunch
1:00-4:30pm | One-on-one Meetings*

*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends June 10th. APPLY HERE

National Cancer Institute Participating Representatives:
Ming Zhao, PhD | Program Director, SBIR Development Center, National Cancer Institute read bio»
Todd Haim, PhD | Program Director, SBIR Development Center, National Cancer Institute read bio»

About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Fees:
Presentation & Lunch Only
$30 | General Public
$40 | General Public Onsite
Includes presentation, Q&A, and lunch. Registration to attend the presentation, Q&A, and lunch will remain open until June 17th or until full.

One-on-One Meeting
FREE | Accepted Companies
Meetings will be held from 1:00pm to 4:30pm for companies. Companies must have applied for a one-on-one meeting ahead of time. To be consider for one-on-one meetings please contact Brittany Connors at [email protected] by June 10th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

National Cancer Institute Representatives' Biographies:
Ming Zhao, PhD | Program Director, SBIR Development Center, National Cancer Institute
Ming Zhao, Ph.D., is a Program Director in the SBIR Development Center at the National Cancer Institute (NCI). In this role, Dr. Zhao develops and manages SBIR/STTR programs and contracts focused on cancer therapeutics, molecular diagnostics and medical imaging. Prior to his appointment at SBIR, Dr. Zhao was a Program Director in the Center to Reduce Cancer Health Disparities (CRCHD) at the NCI. During his tenure at CRCHD, he managed various NCI/NIH programs such as Community Networks Program Centers (CNPC, a program with a total of $117M & 23 Centers) and Geographical Management of Cancer Health Disparities Program (GMaP) as well as R01/R21 grants. Before Dr Zhao joined NCI, he worked as a senior scientist at the GE Global Research Center and as a scientist at Pfizer. Dr. Zhao has broad industrial experience in the development of molecular medicine for early diagnosis of cancer, molecular imaging, the application of human embryonic stem cells, bioinformatics, DNA cloning without cells, biological assay development for bio-compatibility in healthcare applications, and drug discovery in cancer, diabetes, obesity, and central nervous system diseases. Dr. Zhao received his BS/MS degrees from Shandong University, China, and his Ph.D. in molecular biology and biochemistry from the Department of Biological Sciences, Wayne State University. He carried out postdoctoral research at both the University of Michigan Medical School and Wayne State University. Dr. Zhao has published over fifty scientific publications and industrial/technical reports. He has also filed/published eight patents.



Todd Haim, PhD | Program Director, SBIR Development Center, National Cancer Institute
Dr. Todd Haim is a Program Director at the National Cancer Institute's SBIR Development Center. Dr. Haim manages SBIR & STTR grants and contracts related to cancer therapeutics, prevention, and diagnostics. Additionally, Todd plays a key role in the planning, design, and leadership of several center initiatives, including the Investor Forum, evaluation efforts, targeted solicitations, and outreach activities. Prior to starting in the SBIR Development Center, he was a Research Associate and Christine Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences. Dr. Haim staffed the Committee on Science, Engineering and Public Policy (COSEPUP) and his efforts centered on follow-up activities to the 2005 “Rising Above the Gathering Storm” report related to various innovation initiatives and evaluation programs. Previously, he completed a postdoctoral fellowship at Pfizer in which he actively led Pfizer's research efforts in a collaboration with Washington University School of Medicine in St. Louis that illustrated a mechanism for altered cardiac contractility due to excess fatty acids. Dr. Haim graduated from Albert Einstein College of Medicine in January 2007 with a PhD in biomedical research. He has received several prestigious awards and honors including the NJ Governor's Award for Volunteerism in the Field of Health.



About the Meet with... Series:
The purpose of the Meet with Series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, and Thomas McNerney & Partners.


JLABS Bay Area

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact


Related content